NCT05118269终止不适用
Targeted Segmental Vapor Ablation Treatment of Emphysema with Upper Lobe Predominance: a Randomized Controlled Trial of InterVapor® in France - the TARGET Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- Changes in FEV1 between Treatment vs Control at 12 months
研究概览
简要总结
This study is designed to prospectively document changes in FEV1 and health-related quality of life 12 months following sequential segmental treatment with InterVapor® in patients with heterogeneous emphysema with upper lobe predominance. For validity of the study, the results will be compared to patients that receive optimal medical therapy.
详细描述
The primary objectives are to prospectively document changes in FEV1 and health-related quality of life 12 months following sequential segmental treatment with Bronchoscopic Thermal Vapor Ablation (BTVA) using the InterVapor system in patients with heterogeneous emphysema with upper lobe predominance. The French TARGET trial is a prospective, multi-center, single blind, randomized controlled study. 150 participants will be enrolled in the study (1:1 randomization with 75 InterVapor, 75 controls) with a 24-month follow-up period. Subjects randomized to the Control Group may be allowed to cross over to the treatment group and offered the InterVapor treatment once they have completed the protocol defined 12-month follow-up period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 and ≤ 80 years old
- •Heterogeneous emphysema with upper lobe predominance in at least one lung segment to be treated (defined as a Heterogeneity Index (HI) ≥ 1.2 per CT)
- •Post-bronchodilator FEV1 ≥ 15% and ≤ 45% of predicted value
- •Total lung capacity (TLC) ≥ 100% predicted
- •Post-bronchodilator Residual volume (RV) ≥ 200% predicted
- •6-minute walk distance (6MWD) > 100m and ≤ 450m
- •(Partial Pressure of Oxygen) PaCO2 ≤ 45 mm Hg; PaO2 > 45 mm Hg on room air
- •Non-smoking for 4 months prior to study enrollment as confirmed by:
- •negative urine analysis or serum cotinine level of ≤ 10 ng/mL, or negative CO Hb test OR
- •If using smoking cessation product(s) containing nicotine at screening, serum cotinine level ≤ 13.7 ng/ml (or arterial carboxyhemoglobin ≤ 2.5%)
- •Optimized medical management (consistent with GOLD guidelines)
- •Pharmacological:
- •1.Long acting bronchodilator (LABA),Long-acting muscarinic antagonists (LAMA), LAMA + LABA, or LABA + ICS > 1 year
- •b. Evidence of completed Pulmonary Rehabilitation
- •≥ 6 weeks out-patient or ≥ 3 weeks in-patient within 12 months of enrollment; or,
- •Patient has or continues to participate in at home rehabilitation program (i.e. a walking program) within 6 weeks of enrollment under the supervision of a health care professional
- •Mentally and physically able to provide written informed consent to participate in the study. Protected people as defined by the Code de la Sante Publique cannot be included in the study
排除标准
- •DLCO < 20% predicted
- •Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure >45 mm Hg) or evidence or history of cor pulmonale as determined by recent echocardiogram
- •Clinically significant bronchiectasis
- •Clinically significant (greater than 4 tablespoons per day) sputum production.
- •Two (2) or more COPD exacerbations or pneumonia episodes requiring hospitalization in the last year
- •Evidence of active infection in the lungs at the time of procedure.
- •Daily use of systemic steroids, > 10 mg prednisolone (or equivalent) daily.
- •Lung pathology of nodule not proven stable or benign
- •Clinically significant pulmonary fibrosis
- •Prior lung transplant, lung volume reduction surgery (LVRS), bullectomy, or lobectomy
- •Prior lung volume reduction via endobronchial valves(s), coil(s), and/or polymer. Note: Patients whose endobronchial valves have been removed can be treated if: all valves removed ≥ 3 months prior to InterVapor and baseline bronchoscopy reveals no airway obstruction or obvious tissue granulation
- •Large bulla (defined as > 1/3 volume of the lobe)
- •Highly diseased upper and lower lobes in contralateral lung (%-950 HU density >50%)
- •Paraseptal emphysema in any segment targeted for treatment
- •Myocardial Infarction or congestive heart failure within 6 months of screening.
- •Diagnosis of heart failure with Left Ventricular Ejection Fraction (LVEF) < 45% as determined by recent echocardiogram (completed within 3 months prior to screening).
- •Unable to safely discontinue anti-coagulants or platelet inhibitors for 6 weeks post procedure.
- •Body mass index (BMI) > 32 kg/m2
- •Patient taking immunosuppressive drugs for the treatment of cancer, rheumatic arthritis, autoimmune disease, or prevention of tissue or organ rejection.
- •Subject is pregnant or lactating, or plan to become pregnant within the study timeframe
- •Any disease or condition that is likely to limit survival to less than one year
- •Concomitant illnesses or medications that may pose a significant increased risk for complications following treatment with InterVapor®
- •Currently enrolled in another clinical trial studying an experimental treatment.
- •Any condition that would interfere with completion of the study including study assessments and study procedure including bronchoscopy.
结局指标
主要结局
Changes in FEV1 between Treatment vs Control at 12 months
时间窗: 12 months
Percentage change in Forced expiratory volume in 1 second (FEV1) compared to active comparator: Change in FEV1, percent change from baseline to 12 months in FEV1, where FEV1 is expressed in raw units of volume (mL).
St. George's Respiratory Questionnaire for patients with Chronic Obstructive Pulmonary Disease (SGRQ-C) changes between Treatment vs Control at 12 months
时间窗: 12 months
Health-related Qualify of Life (SGRQ-C) compared to active comparator. This is calculated as change from baseline to 12 months in SGRQ-C Total Score. SGRQ-C scores range from 0 to 100. A higher score means a worse outcome.
次要结局
- Improvement in other measures of pulmonary function- Forced Expiratory Volume, Abs, PP change- at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Improvement in other measures of pulmonary function- Residual Volume-Abs at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Improvement in other measures of pulmonary function- Forced Vital Capacity Percent Predicted change- at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Improvement in other measures of pulmonary function- Residual Volume-Percent Predicted value at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Changes in segmental lung volumes from as assessed by CT at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Binary responder analysis to determine minimally clinical important difference for FEV1 at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Improvement in other measures of pulmonary function- Forced Expiratory Volume, Percent change- at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Improvement in other measures of pulmonary function- Residual Volume- at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Improvement in other measures of pulmonary function-Diffusing Capacity of Lung (DLCO)- Absolute Percent Predicted Value at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Number of serious adverse events and fatal events(12 months, 18 months, 24 months)
- Binary responder analysis to determine minimally clinical important difference for Shortness of Breath Questionnaire (SOBQ) score at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Improvement in other measures of pulmonary function- Forced Expiratory Volume, absolute change- at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Improvement in other measures of pulmonary function- Forced Vital Capacity(FVC) change- at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Improvement in other measures of pulmonary function-Diffusing Capacity of Lung (DLCO)- Percent Predicted Value at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Binary responder analysis to determine minimally clinical important difference for SGRQ-C at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Binary responder analysis to determine minimally clinical important difference for COPD Assessment Test (CAT) score at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Improvement in other measures of pulmonary function- Residual Volume-Abs Percent Predicted value at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Changes in pulmonary function tests as assessed by body plethysmography measures at 12, 18 and 24 months(12 months, 18 months, 24 months)
- Binary responder analysis to determine minimally clinical important difference for 6 Minute Walk Distance (6MWD) at 12, 18 and 24 months(12 months, 18 months, 24 months)
研究者
研究点 (2)
Loading locations...
相似试验
终止
不适用
Cardiovascular Improvements With MV ASV Therapy in Heart FailureSleep Disordered BreathingAcute Decompensated Heart FailureNCT01953874ResMed126
招募中
不适用
Clinical Outcomes From Treatment and Evaluation of Obstructive Sleep Apnoea in Children With Down SyndromeObstructive Sleep ApneaDown SyndromeQuality of LifeBehaviorAdherence, TreatmentNCT06030349Children's Health Ireland200
已完成
1 期
Feasibility of VMAT and CBCT for Head and Neck CarcinomasHead and Neck CarcinomaNCT01384890British Columbia Cancer Agency20
已完成
2 期
Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseNCT00782535Chiesi Farmaceutici S.p.A.20
Unknown
不适用
Effectiveness of a VAP Prevention Bundle in the PICUVentilator Associated PneumoniaNCT03763695Fondazione Policlinico Universitario Agostino Gemelli IRCCS242